J. Barbera (Barcelona, Spain), R. Souza (Sao Paulo, Brazil)
The hepatopulmonary syndrome: A study of 105 consecutive patients evaluating natural history and impact of liver transplantation on survival
V. Iyer, S. Karen, R. Cartin-Ceba, M. Krowka (Rochester, United States Of America)
|   |
Pulmonary hypertension, and exercise tolerance in patients with COPD exacerbation
S. Skoczynski, K. Mizia-Stec, A. Semik-Orzech, E. Sozanska, Z. Gasior, W. Pierzchala (Katowice, Poland)
| |
Out of proportion pulmonary hypertension(PH) in COPD
J. Hurdman, R. Condliffe, C. A. Elliot, R. A. Lawson, C. Billings, I. Armstrong, N. Hamilton, J. Wilkinson, I. Sabroe, D. G. Kiely (Sheffield, United Kingdom)
| |
Oral anticoagulation therapy in pediatric pulmonary hypertension: A 10-year registry survival analysis
T. Pulido-Zamudio, J. Gomez-Arroyo, P. Ramirez-Neria, T. Rueda, K. Murillo, E. Santos, K. del Valle, T. Miranda, J. Sandoval (Mexico City, Mexico)
| |
Right ventricular function in highlanders with high altitude pulmonary hypertension and high altitude cor pulmonale
A. Maripov, A. Sarybaev (Bishkek, Kyrgyzstan)
| |
Cardiovascular complications of invasive hemodynamic evaluation in patients with pulmonary hypertension
B. Dias, C. Jardim, A. Hovnanian, S. Hoette, L. Kato, C. Fernandes, R. Souza (Sao Paulo, Brazil)
| |
Impact of therapies on insulin resistance in pulmonary arterial hypertension
A. Hsi, R. Zamanian (United States Of America)
| |
Percent predicted six-minute walk distance and prognosis in PAH
S. Mathai, S. McDevitt, S. Walker, R. Benza, P. Hassoun (Baltimore, Pittsburgh, United States Of America)
| |
Impact of initiation of sildenafil on patterns of healthcare utilization and cost in patients with pulmonary arterial hypertension (PAH)
M. A. Mychaskiw, A. Berger, J. Mardekian, G. Oster (New York, Brookline, United States Of America)
| |
The prognostic value of repeated measurements of N-terminal pro-B-type natriuretic peptide in patients with pulmonary hypertension
G. J. Mauritz, J. Bosboom, H. Groepenhof, N. Westerhof, V. Noordegraaf (Amsterdam, Netherlands)
| |
Hemoptysis in patients with non-Eisenmenger pulmonary arterial hypertension (PAH)– management and prognostic significance
J. Zylkowska, M. Kurzyna, R. Pietura, A. Fijalkowska, M. Florczyk, L. Wawrzynska, M. Szturmowicz, M. Wieteska, J. Burakowski, J. Kober, A. Torbicki (Warsaw, Poland)
| |
Pulmonary hypertension in mitral stenosis is associated with pulmonary venules fibrosis
J. Sandoval, A. Carrillo, F. Masso, V. Soto, T. Pulido, E. Santos, R. Barragan, N. Voelkel (Mexico City, Mexico; Richmond, United States Of America)
| |
Renal dysfunction correlates with impaired hemodynamics and unfavorable outcome in pulmonary arterial hypertension
N. Nickel, P. Kümpers, H. Golpon, K. Olsson, M. Hoeper (Germany)
| |
Three dimensional (3D) analysis of septal curvature from cardiac magnetic resonance images to determine pulmonary hypertension severity
M. Gomberg-Maitland, F. Maffessanti, A. Patel, R. Lang, V. Mor-Avi (Chicago, United States Of America)
| |
Clinical classification of pulmonary hypertension(PH) and implications for survival
J. Hurdman, R. Condliffe, C. A. Elliot, C. Davies, C. Hill, D. Capener, J. Wild, I. Armstrong, N. Hamilton, P. Sephton, I. Sabroe, D. G. Kiely (Sheffield, United Kingdom)
| |
Screening for pulmonary hypertension in sickle cell disease: A regional survey
E. Karampini, D. Parekh, T. Vatopoulou, C. Wright (Birmingham, Dudley, Lyndon, West Bromwich, United Kingdom)
| |
The effect of diluent pH on infection rates in pulmonary hypertension patients on IV treprostinil
J. Rich, M. Wade, S. Coslet, C. Arneson, A. Doran, M. Gomberg-Maitland (Chicago, RTP, United States Of America)
| |
Infections of indwelling central venous catheters among patients treated with intravenous epoprostenol for pulmonary hypertension
D. O‘Callaghan, A. Moutet, X. Jais, F. Parent, L. Savale, D. Natali, A. Yaici, G. Simonneau, M. Humbert, F. Doucet-Populaire, O. Sitbon (Clamart, France)
| |